Paul-Henri WICKY

Dr. Paul-Henri WICKY

Hôpital Bichat-Claude-Bernard, Paris, Île-de-France, France
orcid

Research Focus & Metrics

Representative Publications

View All Publications
1 June 2020 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
FLFrancois-Xavier Lescure
Francois-Xavier Lescure
LBLila Bouadma
Lila Bouadma
DNDuc Nguyen
Duc Nguyen
MPMarion Parisey
Marion Parisey
PWPaul-Henri WICKY
Paul-Henri WICKY
YYYazdan Yazdanpanah
Yazdan Yazdanpanah

22 August 2020 in Journal of Clinical Immunology
Verified
Journal Article
Open access
PDF file
LBLila Bouadma
Lila Bouadma
AWAurélie Wiedemann
Aurélie Wiedemann
JPJuliette Patrier
Juliette Patrier
MSMathieu Surénaud
Mathieu Surénaud
PWPaul-Henri WICKY
Paul-Henri WICKY
YLYves Lévy
Yves Lévy
We report a longitudinal analysis of the immune response associated with a fatal case of COVID-19 in Europe. This patient exhibited a rapid evolution towards multiorgan failure. SARS-CoV-2 was detected in multiple nasopharyngeal, blood, and pleural samples, despite antiviral and immunomodulator treatment. Clinical evolution in the blood was marked by an increase (2–3-fold) in differentiated effector T cells expressing exhaustion (PD-1) and senescence (CD57) markers, an expansion of antibody-secreting cells, a 15-fold increase in γδ T cell and proliferating NK-cell populations, and the total disappearance of monocytes, suggesting lung trafficking. In the serum, waves of a pro-inflammatory cytokine storm, Th1 and Th2 activation, and markers of T cell exhaustion, apoptosis, cell cytotoxicity, and endothelial activation were observed until the fatal outcome. This case underscores the need for well-designed studies to investigate complementary approaches to control viral replication, the source of the hyperinflammatory status, and immunomodulation to target the pathophysiological response. The investigation was conducted as part of an overall French clinical cohort assessing patients with COVID-19 and registered in clinicaltrials.gov under the following number: NCT04262921.

1 September 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
MDMarie Dubert
Marie Dubert
BVBenoit Visseaux
Benoit Visseaux
VIValentina Isernia
Valentina Isernia
LBLila Bouadma
Lila Bouadma
LDLaurène Deconinck
Laurène Deconinck
FLFrancois-Xavier Lescure
Francois-Xavier Lescure
• Remdesivir has been found to be potent in vitro inhibitor of RNA viruses including SARS-CoV-2, but its in vivo potency is still under investigation. • This study report the clinical and biological features of five patients hospitalized with COVID-19 and treated with remdesivir for compassionate use. • For two patients, viral loads in nasopharyngeal samples decreased, despite active replication in the lower respiratory tract area. • The treatment had to be interrupted in four of the five patients, because of ALT elevation and/or renal failure.

6 February 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PWPaul-Henri WICKY
Paul-Henri WICKY
CDClaire Dupuis
Claire Dupuis
CCCharles Cerf
Charles Cerf
SSShidasp Siami
Shidasp Siami
YCYves Cohen
Yves Cohen
jean-francois timsitjean-francois timsit
jean-francois timsit
Introduction: Ventilator-associated pneumonia (VAP) incidence is high among critically ill COVID-19 patients. Its attributable mortality remains underestimated, especially for unresolved episodes. Indeed, the impact of therapeutic failures and the determinants that potentially affect mortality are poorly evaluated. We assessed the prognosis of VAP in severe COVID-19 cases and the impact of relapse, superinfection, and treatment failure on 60-day mortality. Methods: We evaluated the incidence of VAP in a multicenter prospective cohort that included adult patients with severe COVID-19, who required mechanical ventilation for ≥48 h between March 2020 and June 2021. We investigated the risk factors for 30-day and 60-day mortality, and the factors associated with relapse, superinfection, and treatment failure. Results: Among 1424 patients admitted to eleven centers, 540 were invasively ventilated for 48 h or more, and 231 had VAP episodes, which were caused by Enterobacterales (49.8%), P. aeruginosa (24.8%), and S. aureus (22%). The VAP incidence rate was 45.6/1000 ventilator days, and the cumulative incidence at Day 30 was 60%. VAP increased the duration of mechanical ventilation without modifying the crude 60-day death rate (47.6% vs. 44.7% without VAP) and resulted in a 36% increase in death hazard. Late-onset pneumonia represented 179 episodes (78.2%) and was responsible for a 56% increase in death hazard. The cumulative incidence rates of relapse and superinfection were 45% and 39.5%, respectively, but did not impact death hazard. Superinfection was more frequently related to ECMO and first episode of VAP caused by non-fermenting bacteria. The risk factors for treatment failure were an absence of highly susceptible microorganisms and vasopressor need at VAP onset. Conclusions: The incidence of VAP, mainly late-onset episodes, is high in COVID-19 patients and associated with an increased risk of death, similar to that observed in other mechanically ventilated patients. The high rate of VAP due to difficult-to-treat microorganisms, pharmacokinetic alterations induced by renal replacement therapy, shock, and ECMO likely explains the high cumulative risk of relapse, superinfection, and treatment failure.

1 June 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
PWPaul-Henri WICKY
Paul-Henri WICKY
JPJoséphine Poiraud
Joséphine Poiraud
MAManuel Alves
Manuel Alves
JPJuliette Patrier
Juliette Patrier
CDCamille D’humières
Camille D’humières
jean-francois timsitjean-francois timsit
jean-francois timsit
Cefiderocol (FDC) is a siderophore cephalosporin now recognized as a new weapon in the treatment of difficult-to-treat-resistant (DTR) Gram-negative pathogens, including carbapenemase-producing enterobacterales and non-fermentative Gram-negative bacilli (GNB). This article reports our experience with an FDC-based regimen in the treatment of 16 extremely severe patients (invasive mechanical ventilation, 15/16; extracorporeal membrane oxygenation, 9/16; and renal replacement therapy, 8/16) infected with DTR GNB. Our case series provides detailed insight into the pharmacokinetic profile and the microbiological data in real-life conditions. In the narrative review, we discuss the interest of FDC in the treatment of non-fermentative GNB in critically ill patients. We reviewed the microbiological spectrum, resistance mechanisms, pharmacokinetics/pharmacodynamics, efficacy and safety profiles, and real-world evidence for FDC. On the basis of our experience and the available literature, we discuss the optimal FDC-based regimen, FDC dosage, and duration of therapy in critically ill patients with DTR non-fermentative GNB infections.

20 October 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
MLMinh Patrick Lê
Minh Patrick Lê
QHQuentin Le Hingrat
Quentin Le Hingrat
PJPierre Jaquet
Pierre Jaquet
PWPaul-Henri WICKY
Paul-Henri WICKY
VBVincent Bunel
Vincent Bunel
GPGilles Peytavin
Gilles Peytavin
Remdesivir has reported efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and in vivo . Drug-drug interactions limit therapeutic options in transplant patients. Remdesivir and its metabolite GS-441524 are excreted principally in urine. In intensive care unit (ICU) settings, in which multiple-organ dysfunctions can occur rapidly, hemodialysis may be a viable option for maintaining remdesivir treatment, while improving tolerance, by removing both remdesivir’s metabolite (GS-441524) and sulfobutylether β-cyclodextrin sodium (SEBCD).